Memenin Filloides Tümörü
Özet
Filloides tümörleri, nadir görülen ve biyolojik davranışı değişkenlik gösterebilen fibroepitelyal meme tümörleridir. Genellikle hızlı büyüyen, ağrısız, iyi sınırlı kitleler şeklinde ortaya çıkar ve fibroadenomlarla karışabilir. Kesin tanı histolojik inceleme ile konur; bu nedenle şüpheli lezyonlarda kor biyopsi önerilir. Standart tedavi geniş cerrahi eksizyondur. Benign tümörlerde dar cerrahi sınır kabul edilebilirken, malign tümörlerde ≥1 cm negatif sınır tercih edilir. Aksiller lenf nodu tutulumu nadir olduğundan rutin aksiller diseksiyon önerilmez. Sınırda (borderline) ve malign tümörlerde adjuvan radyoterapi lokal nüksü azaltabilir. Kemoterapi yalnızca yüksek riskli veya metastatik hastalarda düşünülmeli ve yumuşak doku sarkomlarına yönelik protokoller uygulanmalıdır. Metastaz en sık akciğerlere yayılır, ancak seçilmiş hastalarda metastazektomi düşünülebilir. Beş yıllık sağkalım malign olgularda %60-80 arasında değişmektedir. Düzenli klinik takip, özellikle ilk iki yıl boyunca nüks açısından kritik öneme sahiptir.
Referanslar
Chaney AW, Pollack A, McNeese MD, et al. Primary treatment of cystosarcoma phyllodes of the breast. Cancer. 2000;89(7):1502–1511. doi:10.1002/1097-0142(20001001)89:7<1502::AID-CNCR13>3.0.CO;2-P.
Reinfuss M, Mituś J, Duda K, et al. The treatment and prognosis of patients with phyllodes tumor of the breast: an analysis of 170 cases. Cancer. 1996;77(5):910–916. doi:10.1002/(sici)1097-0142(19960301)77:5<910::aid-cncr16>3.0.co;2-6.
Bernstein L, Deapen D, Ross RK. The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast. Cancer. 1993;71(10):3020–3024. doi:10.1002/1097-0142(19930515)71:10<3020::AID-CNCR2820711022>3.0.CO;2-G.
Barrio AV, Clark BD, Goldberg JI, et al. Clinicopathologic features and long-term outcomes of 293 phyllodes tumors of the breast. Annals of Surgical Oncology. 2007;14(10):2961–2970. doi:10.1245/s10434-007-9439-z.
Karim RZ, Gerega SK, Yang YH, et al. Phyllodes tumours of the breast: a clinicopathological analysis of 65 cases from a single institution. The Breast. 2009;18(3):165–170. doi:10.1016/j.breast.2009.03.001.
Birch JM, Alston RD, McNally RJ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001;20(34):4621–4628. doi:10.1038/sj.onc.1204621.
Rosenberger LH, Thomas SM, Nimbkar SN, et al. Germline genetic mutations in a multi-center contemporary cohort of 550 phyllodes tumors: an opportunity for expanded multi-gene panel testing. Annals of Surgical Oncology. 2020;27(10):3633–3640. doi:10.1245/s10434-020-08480-z.
Telli ML, Horst KC, Guardino AE, et al. Phyllodes tumors of the breast: natural history, diagnosis, and treatment. Journal of the National Comprehensive Cancer Network. 2007;5(3):324–330. doi:10.6004/jnccn.2007.0027.
Norris HJ, Taylor HB. Relationship of histologic features to behavior of cystosarcoma phyllodes: analysis of ninety-four cases. Cancer. 1967;20(12):2090–2099. doi: 10.1002/1097-0142(196712)20:12<2090::aid-cncr2820201206>3.0.co;2-l.
Macdonald OK, Lee CM, Tward JD, et al. Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer. 2006;107(9):2127–2133. doi:10.1002/cncr.22228.
Mangi AA, Smith BL, Gadd MA, et al. Surgical management of phyllodes tumors. Archives of Surgery. 1999;134(5):487–492; discussion 492–493. doi:10.1001/archsurg.134.5.487.
Wurdinger S, Herzog AB, Fischer DR, et al. Differentiation of phyllodes breast tumors from fibroadenomas on MRI. AJR American Journal of Roentgenology. 2005;185(5):1317–1321. doi:10.2214/AJR.04.1620.
Tan H, Zhang S, Liu H, et al. Imaging findings in phyllodes tumors of the breast. European Journal of Radiology. 2012;81(1):e62–e69. doi:10.1016/j.ejrad.2011.01.085.
Yabuuchi H, Soeda H, Matsuo Y, et al. Phyllodes tumor of the breast: correlation between MR findings and histologic grade. Radiology. 2006;241(3):702–709. doi:10.1148/radiol.2413051470.
Farria DM, Gorczyca DP, Barsky SH, et al. Benign phyllodes tumor of the breast: MR imaging features. AJR American Journal of Roentgenology. 1996;167(1):187–189. doi:10.2214/ajr.167.1.8659370.
Jacklin RK, Ridgway PF, Ziprin P, et al. Optimising preoperative diagnosis in phyllodes tumour of the breast. Journal of Clinical Pathology. 2006;59(5):454–459. doi:10.1136/jcp.2005.025866.
El Hag IA, Aodah A, Kollur SM, et al. Cytological clues in the distinction between phyllodes tumor and fibroadenoma. Cancer Cytopathology. 2010;118(1):33–40. doi:10.1002/cncy.20057.
Dillon MF, Quinn CM, McDermott EW, et al. Needle core biopsy in the diagnosis of phyllodes neoplasm. Surgery. 2006;140(5):779–784. doi:10.1016/j.surg.2006.03.022.
Tan BY, Acs G, Apple SK, et al. Phyllodes tumours of the breast: a consensus review. Histopathology. 2016;68(1):5–21. doi:10.1111/his.12876.
de Roos WK, Kaye P, Dent DM. Factors leading to local recurrence or death after surgical resection of phyllodes tumours of the breast. British Journal of Surgery. 1999;86(3):396–399. doi:10.1046/j.1365-2168.1999.01035.x.
Hawkins RE, Schofield JB, Fisher C, et al. The clinical and histologic criteria that predict metastases from cystosarcoma phyllodes. Cancer. 1992;69(1):141–147. doi:10.1002/1097-0142(19920101)69:1<141::AID-CNCR2820690125>3.0.CO;2-1.
Pietruszka M, Barnes L. Cystosarcoma phyllodes: a clinicopathologic analysis of 42 cases. Cancer. 1978;41(5):1974–1983. doi:10.1002/1097-0142(197805)41:5<1974::AID-CNCR2820410543>3.0.CO;2-C.
Powell CM, Rosen PP. Adipose differentiation in cystosarcoma phyllodes. A study of 14 cases. American Journal of Surgical Pathology. 1994;18(7):720–727. doi:10.1097/00000478-199407000-00008.
Guerrero MA, Ballard BR, Grau AM. Malignant phyllodes tumor of the breast: review of the literature and case report of stromal overgrowth. Surgical Oncology. 2003;12(1):27–37. doi:10.1016/s0960-7404(03)00005-7.
Parker SJ, Harries SA. Phyllodes tumours. Postgraduate Medical Journal. 2001;77(909):428–435. doi:10.1136/pmj.77.909.428.
Belkacémi Y, Bousquet G, Marsiglia H, et al. Phyllodes tumor of the breast. International Journal of Radiation Oncology, Biology, Physics. 2008;70(2):492–500. doi:10.1016/j.ijrobp.2007.06.059.
Barth RJ Jr. Histologic features predict local recurrence after breast conserving therapy of phyllodes tumors. Breast Cancer Research and Treatment. 1999;57(3):291–295. doi:10.1023/A:1006260225618.
Tan PH, Thike AA, Tan WJ, et al. Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. Journal of Clinical Pathology. 2012;65(1):69–76. doi:10.1136/jclinpath-2011-200368.
Carter BA, Page DL. Phyllodes tumor of the breast: local recurrence versus metastatic capacity. Human Pathology. 2004;35(9):1051–1052. doi:10.1016/j.humpath.2004.08.001.
Karim RZ, O'Toole SA, Scolyer RA, et al. Recent insights into the molecular pathogenesis of mammary phyllodes tumours. Journal of Clinical Pathology. 2013;66(6):496–505. doi:10.1136/jclinpath-2012-201082.
Kuijper A, Buerger H, Simon R, et al. Analysis of the progression of fibroepithelial tumours of the breast by PCR-based clonality assay. The Journal of Pathology. 2002;197(5):575–581. doi:10.1002/path.1161.
Tan J, Ong CK, Lim WK, et al. Genomic landscapes of breast fibroepithelial tumors. Nature Genetics. 2015;47(11):1341–1345. doi:10.1038/ng.3409.
Ng CC, Tan J, Ong CK, et al. MED12 is frequently mutated in breast phyllodes tumours: a study of 112 cases. Journal of Clinical Pathology. 2015;68(9):685–691. doi:10.1136/jclinpath-2015-202896.
Cani AK, Hovelson DH, McDaniel AS, et al. Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors. Molecular Cancer Research. 2015;13(4):613–619. doi:10.1158/1541-7786.MCR-14-0578.
NCCN Guidelines Version 1.2025 Breast Cancer 2025. National Comprehensive Cancer Network. Available from: www.nccn.org. (Accessed on February 24, 2025).
Jang JH, Choi MY, Lee SK, et al. Clinicopathologic risk factors for the local recurrence of phyllodes tumors of the breast. Annals of Surgical Oncology. 2012;19(8):2612–2617. doi: 10.1245/s10434-012-2307-5.
Rosenberger LH, Thomas SM, Nimbkar SN, et al. Contemporary multi-institutional cohort of 550 cases of phyllodes tumors (2007-2017) demonstrates a need for more individualized margin guidelines. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2021;39(3):178–189. doi:10.1200/JCO.20.02647.
Spitaleri G, Toesca A, Botteri E, et al. Breast phyllodes tumor: a review of literature and a single center retrospective series analysis. Critical Reviews in Oncology/Hematology. 2013;88(2):427–436. doi:10.1016/j.critrevonc.2013.06.005.
Moutte A, Chopin N, Faure C, et al. Surgical management of benign and borderline phyllodes tumors of the breast. The Breast Journal. 2016;22(5):547–552. doi:10.1111/tbj.12623.
Ouyang Q, Li S, Tan C, et al. Benign phyllodes tumor of the breast diagnosed after ultrasound-guided vacuum-assisted biopsy: surgical excision or wait-and-watch? Annals of Surgical Oncology. 2016;23(4):1129–1134. doi:10.1245/s10434-015-4990-5.
Barth RJ Jr, Wells WA, Mitchell SE, et al. A prospective, multi-institutional study of adjuvant radiotherapy after resection of malignant phyllodes tumors. Annals of Surgical Oncology. 2009;16(8):2288–2294. doi: 10.1245/s10434-009-0489-2.
Zeng S, Zhang X, Yang D, et al. Effects of adjuvant radiotherapy on borderline and malignant phyllodes tumors: A systematic review and meta-analysis. Molecular and Clinical Oncology. 2015;3(3):663–671. doi:10.3892/mco.2015.503.
Chao X, Chen K, Zeng J, et al. Adjuvant radiotherapy and chemotherapy for patients with breast phyllodes tumors: a systematic review and meta-analysis. BMC Cancer. 2019;19(1):372. doi: 10.1186/s12885-019-5585-5.
Oladeru OT, Yang DD, Ma SJ, et al. Patterns of care and predictors of adjuvant radiation therapy in phyllodes tumor of the breast. The Breast Journal. 2020;26(7):1352–1357. doi: 10.1111/tbj.13830.
Zhao W, Tian Q, Zhao A, et al. The role of adjuvant radiotherapy in patients with malignant phyllodes tumor of the breast: a propensity-score matching analysis. Breast Cancer. 2021;28(1):110-118. doi: 10.1007/s12282-020-01135-7.
Gnerlich JL, Williams RT, Yao K, et al. Utilization of radiotherapy for malignant phyllodes tumors: analysis of the National Cancer Data Base, 1998-2009. Annals of Surgical Oncology. 2014;21(4):1222-1230. doi: 10.1245/s10434-013-3395-6.
Gutnik L, Ren Y, Thomas SM, et al. Malignant phyllodes tumor and primary breast sarcoma; distinct rare tumors of the breast. Journal of Surgical Oncology. 2022;125(6):947-957. doi: 10.1002/jso.26820.
Sars C, Sackey H, Frisell J, et al. Current clinical practice in the management of phyllodes tumors of the breast: an international cross-sectional study among surgeons and oncologists. Breast Cancer Research and Treatment. 2023;199(2):293-304. doi: 10.1007/s10549-023-06896-1.
Morales-Vásquez F, Gonzalez-Angulo AM, Broglio K, et al. Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast. Breast Journal. 2007;13(6):551-556. doi: 10.1111/j.1524-4741.2007.00510.x.
Burton GV, Hart LL, Leight GS Jr, et al. Cystosarcoma phyllodes. Effective therapy with cisplatin and etoposide chemotherapy. Cancer. 1989;63(11):2088-2092. doi: 10.1002/1097-0142(19890601)63:11<2088::aid-cncr2820631103>3.0.co;2-c.
Sapino A, Bosco M, Cassoni P, et al. Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast. Modern Pathology. 2006;19(4):599-606. doi: 10.1038/modpathol.3800574.
Patel SR, Zagars GK, Pisters PW. The follow-up of adult soft-tissue sarcomas. Seminars in Oncology. 2003;30(3):413-416. doi: 10.1016/s0093-7754(03)00101-5.
Borhani-Khomani K, Talman ML, Kroman N, et al. Risk of local recurrence of benign and borderline phyllodes tumors: A Danish population-based retrospective study. Annals of Surgical Oncology. 2016;23(5):1543-1548. doi: 10.1245/s10434-015-5041-y.
Lu Y, Chen Y, Zhu L, et al. Local recurrence of benign, borderline, and malignant phyllodes tumors of the breast: A systematic review and meta-analysis. Annals of Surgical Oncology. 2019;26(5):1263-1275. doi: 10.1245/s10434-018-07134-5.
Neron M, Sajous C, Thezenas S, et al. Impact of metastasis surgery and alkylating-agent-based chemotherapy on outcomes of metastatic malignant phyllodes tumors: A multicenter retrospective study. Annals of Surgical Oncology. 2020;27(5):1693-1699. doi: 10.1245/s10434-019-08097-x.
Samii E, Hurni Y, Huber D. Management and outcomes of metastatic and recurrent malignant phyllodes tumors of the breast: A systematic literature review. European Journal of Breast Health. 2023;19(3):191-200. doi: 10.4274/ejbh.galenos.2023.2023-3-2.
Hawkins RE, Schofield JB, Wiltshaw E, et al. Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes. Cancer. 1992;69(9):2271-2275. doi: 10.1002/1097-0142(19920501)69:9<2271::aid-cncr2820690911>3.0.co;2-7.
Mituś JW, Blecharz P, Walasek T, et al. Treatment of patients with distant metastases from phyllodes tumor of the breast. World Journal of Surgery. 2016;40(2):323-328. doi: 10.1007/s00268-015-3262-7.
Palassini E, Mir O, Grignani G, et al. Systemic treatment in advanced phyllodes tumor of the breast: a multi-institutional European retrospective case-series analysis. Breast Cancer Research and Treatment. 2022;192(3):603-610. doi: 10.1007/s10549-022-06524-4.
Parkes A, Wang WL, Patel S, et al. Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Research and Treatment. 2021;186(3):871-882. doi: 10.1007/s10549-021-06116-8.
Confavreux C, Lurkin A, Mitton N, et al. Sarcomas and malignant phyllodes tumours of the breast—A retrospective study. European Journal of Cancer (Oxford, England: 1990). 2006;42(16):2715-2721. doi: 10.1016/j.ejca.2006.05.040.
Spanheimer PM, Murray MP, Zabor EC, et al. Long-term outcomes after surgical treatment of malignant/borderline phyllodes tumors of the breast. Annals of Surgical Oncology. 2019;26(7):2136-2143. doi: 10.1245/s10434-019-07210-4.
